SPARC successfully enrolls 506 patients in Parkinson's study

Sun Pharma Advanced Research Company Ltd. (SPARC) has successfully enrolled 506 patients in a global Phase 2 study, PROSEEK, focused on early Parkinson's disease treatment. Conducted across 84 sites in the US, Europe, and India, this study is one of the largest of its kind.

PROSEEK investigates the safety and efficacy of Abl tyrosine kinase inhibition through K0706 (Vodobatinib) in early-stage Parkinson's disease. The study follows a randomized, double-blind, placebo-controlled design.

CEO of SPARC, Anil Raghavan, expressed his gratitude to the patients, caregivers, and physicians involved in PROSEEK, highlighting it as a significant milestone for both SPARC and Vodobatinib.

This achievement marks a substantial step forward in Parkinson's research and brings hope for improved treatment options for those in the early stages of the disease. The comprehensive nature of the study, spanning multiple regions, demonstrates a global effort to address this challenging medical condition.